Treatment of benign nodular goitre with mildly suppressive doses of L‐thyroxine: effects on bone mineral density and on nodule size

Abstract

L-thyroxine (LT4) treatment at doses slightly suppressing TSH does not significantly affect bone mineralization, nor does it represent a risk factor for osteoporosis, even in postmenopausal patients. The efficacy of this therapeutic schedule on goitre size is comparable with the effects previously reported with suppressive doses.